Peanut-specific Immunoglobulin E (Peanut sIgE)

Peanut-specific Immunoglobulin E (IgE) is a specialized antibody produced by the immune system in individuals sensitized to peanut proteins, such as Ara h 1, Ara h 2, and Ara h 3 (Sutton & Gould, 1993). These antibodies circulate in the blood and bind with high affinity to the FcεRI receptor on the surface of effector cells, primarily mast cells and basophils (Gould & Sutton, 2008). When a sensitized individual is exposed to peanuts, the allergens cross-link these surface-bound IgE molecules, triggering the immediate release of inflammatory mediators like histamine and leukotrienes (Galli & Tsai, 2012). This physiological cascade is responsible for the clinical manifestations of peanut allergy, which can range from localized hives to systemic anaphylaxis (Sicherer & Sampson, 2018). Therapeutic approaches include the use of monoclonal antibodies like omalizumab, which bind to free IgE and prevent it from attaching to effector cells, thereby increasing the allergen threshold required to trigger a reaction (Wood et al., 2024). Other strategies, such as oral immunotherapy, aim to gradually desensitize the patient by modulating the IgE-mediated response over time (FDA, 2020).

Other names

Peanut-specific IgEArachis hypogaea-specific IgEsIgE to peanut allergensIgE-FcεRI complex (peanut-specific)

Anti-IgE monoclonal antibodies bind to the Cε3 domain of free IgE, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils (Wood et al., 2024). This sequestration reduces the density of IgE on effector cells and downregulates receptor expression, thereby inhibiting allergen-induced degranulation (Gould & Sutton, 2008). Downstream inhibitors, such as BTK inhibitors, target the signaling pathways initiated by the cross-linking of IgE-FcεRI complexes on these cells (Angany et al., 2023).